Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Capital Expenditures (2022 - 2024)

Atara Biotherapeutics' Capital Expenditures history spans 3 years, with the latest figure at $90000.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures fell 19.64% year-over-year to $90000.0; the TTM value through Sep 2025 reached $90000.0, down 66.42%, while the annual FY2024 figure was $246000.0, 86.36% up from the prior year.
  • Capital Expenditures reached $90000.0 in Q4 2024 per ATRA's latest filing, up from $29000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4.2 million in Q4 2022 to a low of -$2.5 million in Q2 2022.
  • Average Capital Expenditures over 3 years is $415545.5, with a median of $90000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 97.31% in 2023, then skyrocketed 133.72% in 2024.
  • A 3-year view of Capital Expenditures shows it stood at $4.2 million in 2022, then plummeted by 97.31% to $112000.0 in 2023, then dropped by 19.64% to $90000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATRA's Capital Expenditures are $90000.0 (Q4 2024), $29000.0 (Q2 2024), and $127000.0 (Q1 2024).